Please login to the form below

ceftazidime

This page shows the latest ceftazidime news and features for those working in and with pharma, biotech and healthcare.

Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought

Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle

Latest news

Pfizer launches new antibiotic Zavicefta in UK and Germany

The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
AZ slims down again with sale of antibiotics to Pfizer

The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
AZ gets EU green light for new antibiotic Zavicefta

The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization.
Merck starts pivotal trials of new antibiotic combination

aeruginosa. AstraZeneca (AZ) recently secured CHMP backing in Europe for Zavicefta - which combines established cephalosporin antibiotic ceftazidime with new-generation beta lactamase inhibitor avibactam.
CHMP backs AZ's 'superbug' antibiotic product

The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Zavicefta (ceftazidime/avibactam), which combines an established antibiotic with a new drug designed to overcome bacterial resistance. ... In the US, Actavis (now operating

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Deal Watch August 2016

14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....